Kernodle & Katon Asset Management Group’s Pfizer PFE Stock Holding History

Kernodle & Katon Asset Management Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$338K	Buy	10,423 +1,771	+20%	+$55.8K	0.2%	72
2016 Q4	$267K	Sell	8,652 -1,525	-15%	-$46.6K	0.16%	76
2016 Q3	$327K	Sell	10,177 -133	-1%	-$4.45K	0.2%	73
2016 Q2	$344K	Sell	10,310 -212	-2%	-$6.77K	0.32%	38
2016 Q1	$296K	Buy	10,522 +559	+6%	+$16K	0.28%	40
2015 Q4	$305K	Buy	+9,963	New	+$313K	0.29%	19

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kernodle & Katon Asset Management Group's PFE Position: Q1 2017 in Review

Kernodle & Katon Asset Management Group increased its Pfizer (PFE) stake by 20% in Q1 2017, buying an estimated $55.8K and bringing the position to 10,423 shares worth $338K. The position accounts for 0.2% of the portfolio, ranked #72.

Kernodle & Katon Asset Management Group first reported a position in PFE in Q4 2015 and has held it in 6 quarters since. The position peaked at $344K in Q2 2016. 2,074 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

Kernodle & Katon Asset Management Group held 10,423 shares of Pfizer worth $338K as of Q1 2017.
Kernodle & Katon Asset Management Group bought 1,771 Pfizer shares in Q1 2017, an estimated $55.8K.
Pfizer made up 0.2% of Kernodle & Katon Asset Management Group's portfolio in Q1 2017, its #72 holding.
Kernodle & Katon Asset Management Group first reported a position in Pfizer in Q4 2015 and has held it in 6 quarters since.
Kernodle & Katon Asset Management Group's Pfizer position peaked at $344K in Q2 2016.
2,074 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Kernodle & Katon Asset Management Group's 13F filing for Q1 2017, filed 12 May 2017.